Literature DB >> 16690107

Body weight and composition changes in ovarian cancer patients during adjuvant chemotherapy.

Karen M Gil1, Heidi E Frasure, Michael P Hopkins, Eric L Jenison, Vivian E von Gruenigen.   

Abstract

OBJECTIVE: To prospectively examine body weight changes in women with newly diagnosed ovarian cancer receiving surgery and adjuvant chemotherapy. Body composition was examined in a subset of these women.
METHODS: Body weight (BW) and body composition, using bioelectrical impedance (RJL Systems Inc.), were prospectively measured pre- and post-operatively, and at 3, 6, and 12 months.
RESULTS: Mean age of 42 women was 59 years and did not differ by stage of disease. Nine women with early stage disease did not receive adjuvant chemotherapy. Mean BW of 33 patients receiving chemotherapy decreased from the pre- to post-operative visit and then returned to baseline levels by 12 months (F = 8.70, P = 0.003). Nine patients who did not receive chemotherapy demonstrated a similar pattern (F = 7.0, P = 0.002). Women receiving chemotherapy with stage I/II cancer had a 2.8 +/- 2.0 kg weight gain over the year, and women with stage III/IV cancer had a 1.5 +/- 1.5 kg weight loss (t = 1.72, P = 0.096). A subset of women with stage I/II (n = 6) and stage III/IV (n = 6) ovarian cancer receiving chemotherapy had body composition measured at three time points. Absolute body fat changes paralleled changes in BW (F = 9.95, P = 0.002).
CONCLUSIONS: Our study is the first prospective evaluation of body weight and composition in women undergoing surgery and chemotherapy for ovarian cancer. These results demonstrate that women undergoing surgery for ovarian cancer lost weight following surgery and regained it slowly over the following year. Further investigations of weight changes during adjuvant chemotherapy are indicated to assess potential changes in different stages of disease.

Entities:  

Mesh:

Year:  2006        PMID: 16690107     DOI: 10.1016/j.ygyno.2006.03.005

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

1.  Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.

Authors:  L M Hess; R Barakat; C Tian; R F Ozols; D S Alberts
Journal:  Gynecol Oncol       Date:  2007-08-06       Impact factor: 5.482

2.  Body weight changes in patients undergoing chemotherapy for ovarian cancer influence progression-free and overall survival.

Authors:  Marcin Mardas; Marta Stelmach-Mardas; Radosław Madry
Journal:  Support Care Cancer       Date:  2016-10-22       Impact factor: 3.603

Review 3.  Body Composition and Anti-Neoplastic Treatment in Adult and Older Subjects - A Systematic Review.

Authors:  S Gérard; D Bréchemier; A Lefort; S Lozano; G Abellan Van Kan; T Filleron; L Mourey; C Bernard-Marty; M E Rougé-Bugat; V Soler; B Vellas; M Cesari; Y Rolland; L Balardy
Journal:  J Nutr Health Aging       Date:  2016       Impact factor: 4.075

4.  The impact of body weight on ovarian cancer outcomes.

Authors:  Floor J Backes; Christa I Nagel; Elizabeth Bussewitz; Jessica Donner; Erinn Hade; Ritu Salani
Journal:  Int J Gynecol Cancer       Date:  2011-12       Impact factor: 3.437

Review 5.  Energy balance in cancer survivors at risk of weight gain: a review.

Authors:  Jessica McNeil
Journal:  Eur J Nutr       Date:  2022-08-19       Impact factor: 4.865

6.  Effect of exercise on body composition among women with ovarian cancer.

Authors:  Anlan Cao; Brenda Cartmel; Fang-Yong Li; Linda T Gottlieb; Maura Harrigan; Jennifer A Ligibel; Radhika Gogoi; Peter E Schwartz; Melinda L Irwin; Leah M Ferrucci
Journal:  J Cancer Surviv       Date:  2022-04-04       Impact factor: 4.062

Review 7.  Impact of Body Weight and Body Composition on Ovarian Cancer Prognosis.

Authors:  Sarah A Purcell; Sarah A Elliott; Candyce H Kroenke; Michael B Sawyer; Carla M Prado
Journal:  Curr Oncol Rep       Date:  2016-02       Impact factor: 5.075

8.  Investigating the clinical significance of body composition changes in patients undergoing chemoradiation for oropharyngeal cancer using analytic morphomics.

Authors:  Chen Wang; Jeffrey M Vainshtein; Maria Veksler; Patrick E Rabban; June A Sullivan; Stewart C Wang; Avraham Eisbruch; Shruti Jolly
Journal:  Springerplus       Date:  2016-04-11

9.  Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia.

Authors:  Fabrizio Pin; Rafael Barreto; Yukiko Kitase; Sumegha Mitra; Carlie E Erne; Leah J Novinger; Teresa A Zimmers; Marion E Couch; Lynda F Bonewald; Andrea Bonetto
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-07-15       Impact factor: 12.910

10.  Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro-oesophageal cancer.

Authors:  R B den Boer; K I Jones; S Ash; G I van Boxel; R S Gillies; T O'Donnell; J P Ruurda; B Sgromo; M A Silva; N D Maynard
Journal:  BJS Open       Date:  2020-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.